- Home
- WU vs TARS Comparison
WU vs TARS Comparison
Compare WU & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WU | TARS |
|---|---|---|
| Founded | 1851 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.7B |
| IPO Year | 2006 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WU | TARS |
|---|---|---|
| Price | $7.33 | $72.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $9.00 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 11.5M | 682.9K |
| Earning Date | 04-24-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.47% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $4,050,700,000.00 | $451,360,000.00 |
| Revenue This Year | $8.50 | $56.43 |
| Revenue Next Year | $4.73 | $30.19 |
| P/E Ratio | $16.21 | ★ N/A |
| Revenue Growth | N/A | ★ 146.71 |
| 52 Week Low | $6.27 | $48.20 |
| 52 Week High | $10.35 | $85.25 |
Technical Indicators
Market Signals| Indicator | WU | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 67.83 |
| Support Level | $6.91 | $60.95 |
| Resistance Level | $7.52 | $74.39 |
| Average True Range (ATR) | 0.21 | 3.08 |
| MACD | 0.03 | 0.67 |
| Stochastic Oscillator | 75.40 | 95.53 |
Price Performance
Historical ComparisonAbout WU Western Union Company (The)
Western Union provides domestic and international money transfers through its global network of over 500,000 outside agents. The company handled almost 290 million transactions in 2025 and is the largest money transfer company in the world.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.